MedTrace Logo

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

NCT00291616 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2011-07-21

No results posted yet for this study

Summary

The purpose of this study is to determine the optimal treatment duration of antiviral therapy for chronic hepatitis B.

Conditions

Interventions

DRUG

Pegylated Interferon-alpha2a

180 microgram s.c. injection weekly

DRUG

Thymosin alpha1 & Pegylated Interferon-alpha2a

Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • SciClone Pharmaceuticals

    collaborator INDUSTRY

  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jung H Yoon, M.D. · Seoul National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-12-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00291616 on ClinicalTrials.gov